Endpoints
SECONDARY, REMISSION
The primary endpoint was change from baseline (CFB) in the HAMD-17 total score at D3. The key secondary efficacy endpoint was CFB in HAMD-17 total score over the double-blind treatment period, using equal weights for the scheduled visits (D3, D8, D12, and D15).Other secondary efficacy endpoints included CFB in HAMD-17 total score at D15 and D42; CFB in the HAMD-17 total score around the end of blinded treatment (using equal weights for the scheduled visits at D12, D15, and D18); HAMD-17 response, defined as ≥50% reduction from baseline in HAMD-17 total score at D15 and D42; time to first HAMD-17 response; and HAMD-17 remission, defined as HAMD-17 total score ≤7, at D15 and D42. Several other secondary endpoints were assessed and are described in the 